Latest Biotech News

Gilead Sciences agreed to buy Tubulis for up to $5 billion, expanding the pharma’s antibody-drug conjugate (ADC) toolkit beyond its Trodelvy and strengthening clinical ADC depth. The deal includes...

Jeito Capital closed its second flagship fund at more than €1 billion ($1.2 billion), exceeding targets and marking a record for an independent European biopharma-focused fund. The vehicle, Jeito...

Sidewinder Therapeutics emerged from stealth with an oversubscribed $137 million Series B to advance bispecific antibody-drug conjugate programs toward the clinic. The San Diego company’s plan...

Biotechnology industry advocates warned that drug price controls resembling Most Favored Nation (MFN) policies could worsen affordability and access. In BIO’s March Coffee Chat, Karin Hoelzer,...

Avalyn Pharma filed for an IPO to fund late-stage development of inhaled formulations of approved pulmonary fibrosis drugs. The company is preparing to move AP01 (inhaled pirfenidone) from an...

Biogen reported a second Phase II success for litifilimab in cutaneous lupus erythematosus (CLE), reinforcing BDCA2 as a therapeutic target in refractory disease. The company said the latest...

Waters received FDA 510(k) clearance for the BD Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, enabling at-home self-collection for high-risk HPV screening. The company said the...

Amplia Therapeutics halted recruitment in its Phase II Amplicity trial in advanced pancreatic cancer after three dose-limiting toxicities tied to the modified FOLFIRINOX chemotherapy backbone...

Grail and Epic reached an integration milestone to expand ordering of the Galleri multi-cancer early detection test inside Epic electronic health records. Grail said clinicians will be able to...

Blackstone and TPG completed their acquisition of Hologic, taking the molecular diagnostics company private after a deal valued at up to $18.3 billion announced in October 2025. Hologic...

Gilead Sciences agreed to acquire German biotech Tubulis for $3.15 billion upfront and up to $1.85 billion in milestone payments, adding next-generation antibody-drug conjugate (ADC) capabilities...

Neurocrine Biosciences agreed to acquire Soleno Therapeutics in a $2.9 billion deal designed to expand its marketed endocrinology and rare disease portfolio. The transaction includes Vykat XR...

Avalyn Pharma filed for an initial public offering as a pulmonary fibrosis biotech developing inhaled formulations of approved oral medicines. The company’s filing signals it is seeking...

Sidewinder Therapeutics, a next-generation antibody-drug conjugate startup, secured an oversubscribed $137 million Series B to fund development of bispecific ADCs. The company plans to move a lead...

New coverage highlights how large language models are being applied to biology and chemistry research using the growing availability of large molecular and experimental datasets. The article...

Researchers reported in Cell Research that GSK3α acts as a universal “stemness checkpoint” regulating stem cell identity across multiple stem cell types and developmental contexts. The work...

Scientists at UCSF published a high-resolution single-cell spatiotemporal atlas of the human maternal–fetal interface in Nature, mapping cell types across normal pregnancy and linking them to...

The FDA’s 2027 budget proposal lays out regulatory reforms aimed at expediting development and review, including making the rare pediatric disease priority review voucher program permanent. If...

CellCarta and Lunit entered a partnership to integrate AI pathology solutions into clinical trial workflows and biomarker development. The collaboration pairs CellCarta’s global clinical pathology...

Syneron Bio secured more than $250 million in venture funding as it builds a platform in macrocyclic peptides, and also announced a multi-billion-dollar deal with AstraZeneca. The financing and...